Phase II Study of WT1 126-134 Peptide Vaccination in Combination With Adjuvants GM-CSF and KLH in AML
In this phase II trial HLA-A2+ patients with active AML without curative treatment option
are vaccinated with WT1 126-134 peptide mixed with adjuvant KLH as T-helper protein and
GM-CSF 4 times bi-weekly, then monthly.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Generation of T cell response
Ulrich Keilholz, MD
Germany: Federal Institute for Drugs and Medical Devices